| Title: |
Melissa phospholipids improves sleep quality and mental well-being: concluding results from clinical study in adults with emotional distress |
| Authors: |
Rondanelli M.; Mazzola G.; Barrile G. C.; Misiano P.; Perna S. |
| Contributors: |
M. Rondanelli; G. Mazzola; G.C. Barrile; P. Misiano; S. Perna |
| Publisher Information: |
Swedish Nutrition Foundation |
| Publication Year: |
2026 |
| Collection: |
The University of Milan: Archivio Istituzionale della Ricerca (AIR) |
| Subject Terms: |
Melissa; lemon balm; sleep quality; emotional well-being; anxiety; emotional distre; Phytosome; phospholipid; rosmarinic acid; Settore MEDS-08/C - Scienza dell'alimentazione e delle tecniche dietetiche applicate |
| Description: |
Background: Melissa officinalis L. (lemon balm) is a botanical support widely used for its calming and sleep-promoting properties. Objective: To evaluate the impact of daily supplementation with Melissa phospholipids (MOP) at 200 or 400 mg for 3 weeks on sleep quality and psychological well-being in adults with emotional distress and poor sleep quality. Design: This prospective, open-label, dose-comparison clinical study enrolled 32 adults with poor sleep quality and/ or clinically significant emotional distress. Participants received daily supplementation with either 200 or 400 mg/day MOP for 3 weeks. Sleep quality (primary endpoint) was assessed using the Pittsburgh Sleep Quality Index (PSQI) at baseline (T0), and week 3 (T1). Secondary endpoints included depression, anxiety, and stress, positive and negative affect, mental well-being, and quality of life. Safety was also assessed through adherence monitoring, documentation of side effects or adverse events, and by routine blood biochemistry parameters of liver and renal functions. Results: PSQI scores significantly improved over time (P < 0.0001), with greater and earlier benefits at 400 mg/ day (−30% vs. −15%; P < 0.05). The 400 mg dose also produced significant reductions in depression (−26%), anxiety (−18%), and stress (−22%) scores (all P < 0.001), together with increased positive and negative affect together with Warwick-Edinburgh Mental Well-Being Scale (+15%). Quality of life improved across total score (33%) and its four domains, with significant results in physical well-being (P < 0.05). No statistically significant changes in safety parameters were detected and no adverse effects were reported. Discussion: MOP, particularly at 400 mg/day, confirmed to significantly improve sleep and life quality, mood, and overall mental well-being. Conclusion: These findings support and extend the health benefits of MOP as a well-tolerated, safe natural approach in a dose-dependent frame to managing sleep quality and emotional distress. Future ... |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
info:eu-repo/semantics/altIdentifier/pmid/41777239; volume:70; firstpage:1; lastpage:10; numberofpages:10; journal:FOOD & NUTRITION RESEARCH; https://hdl.handle.net/2434/1231593 |
| DOI: |
10.29219/fnr.v70.13729 |
| Availability: |
https://hdl.handle.net/2434/1231593; https://doi.org/10.29219/fnr.v70.13729 |
| Rights: |
info:eu-repo/semantics/openAccess ; license:Creative commons ; license uri:http://creativecommons.org/licenses/by/4.0/ |
| Accession Number: |
edsbas.F7DECF81 |
| Database: |
BASE |